Highest safety standards
Start your intake Semaglutide and Depression: What the Clinical Data Shows Clinical trials of semaglutide for weight loss (STEP program) did not show statistically significant increases in depression compared to placebo
The 2026 EASO pharmacotherapy update formalised this evidence by ranking tirzepatide above semaglutide for obesity management, while simultaneously supporting semaglutide as the better-documented agent for liver fibrosis improvement in metabolic dysfunction-associated steatohepatitis (MASH), based on more mature phase 3 ESSENCE trial data [1]
Kurajoh M, Fukumoto S, Yoshida S, Akari S, Murase T, Nakamura T, Ishii H, Yoshida H, Nagata Y, Morioka T, Mori K, Imanishi Y, Hirata K, Emoto M
Nirmal AJ, Regan T, Shih BB, Hume DA, Sims AH, Freeman TC
israeldrugs.health.gov.il Kelly AS, Auerbach P, Barrientos-Perez M, et al